Background Ethiopia has shown notable progress in reducing the burden of malaria over the past two decades. Because of this progress, the country has shifted efforts from control to elimination of malaria. This study was conducted to analyse the malaria epidemiology and stratification of incidence in the malaria elimination setting in eastern Ethiopia. Methods A retrospective study was conducted to analyse the epidemiology of malaria by reviewing the district health office data from 2013 to 2019 in Harari Region. In addition, three years of sub-district level malaria data were used to stratify the malaria transmission intensity. Malaria interventions (Long-lasting insecticidal nets [LLIN] and indoor residual spraying [IRS]) employed were reviewed to analyse the intervention coverage at the Regional level. Descriptive statistics were used to show the malaria transmission in terms of years, season and species of the malaria parasite. Incidence rate per 1000 population and death rate per 1 000 000 population at risk were computed using the total population of each year. Results In the Harari Region, malaria incidence showed a more pronounced declining trend from 2017 to 2019. Plasmodium falciparum, P. vivax and mixed infections accounted for 69.2%, 30.6% and 0.2% of the cases, respectively. There was an increment in malaria intervention coverage and improved malaria diagnosis. In the year 2019 the coverage of LLIN and IRS in the Region were 93.4% and 85.1% respectively. The annual malaria incidence rate dropped from 42.9 cases per 1000 population in 2013 to 6.7 cases per 1000 population in 2019. Malaria-related deaths decreased from 4.7 deaths per 1 000 000 people annually in 2013 to zero, and there have been no deaths reported since 2015. The malaria risk appears to be heterogeneous and varies between districts. A higher number of malaria cases were recorded in Erer and Jenella districts, which constitute 62% of the cases in the Region. According to the sub-district level malaria stratification, there was shrinkage in the malaria transmission map and about 70% of the sub-districts have achieved elimination targets. Conclusions In the Harari Region, malaria morbidity and mortality have been significantly declined. Thus, if this achievement is sustained and scaling-up of the existing malaria prevention and control strategies by focusing on those populations living in the higher malaria transmission districts and sub-districts, planning of malaria elimination from the study area might be feasible.
Background: Ethiopia has shown a notable progress in reducing the burden of malaria over the last two decades. Based on the progress, the country shifted from control to elimination of malaria. This study was conducted to analyse trends in malaria cases and stratification of malaria incidence in the malaria elimination setting in eastern Ethiopia. Methods: A retrospective malaria data recorded from 2013 to 2019 were reviewed from Harari Region, eastern Ethiopia. In addition, three years malaria data were used to assess the sub-district ( kebele ) level stratification of malaria incidence. Results: A total of 44,882 (46.9%) malaria cases were detected from 95,629 malaria-suspected outpatient diagnosed in Harari Region from 2013 to 2019. Of these, 41,046 were confirmed malaria cases (microscopically and rapid diagnostic test) while 3,836 were reported as clinical cases. In the region, malaria trend was fluctuating year to year, the high peak was reported in 2016 but malaria cases showed decreasing trend in number of malaria cases from 2017 to 2019. Plasmodium falciparum , P. vivax and mixed infections were accounted for 69.2%, 30.6% and 0.2% of the cases, respectively. The malaria risk appears to be heterogeneous and varies between districts, higher number of malaria cases were recorded in Jenella, Erer and Amir Nur districts, and about 80% of the cases were from these districts. According to the latest (2019) sub-district ( kebele ) level epidemiological data of malaria stratification, 8.3% of the sub-districts in the Harari region reported no malaria and a majority (61.1%) of sub-districts reported fewer than five cases per thousand population. Furthermore, there were no high malaria strata in the Region. The highest peak of malaria cases in the Region was reported from September to November followed by from April to May. Conclusions: In the Harari Region, the retrospective malaria data showed a significant declining trend. Thus, if this achievement is sustained and scaling-up of the existing malaria prevention and control strategies by focusing on those populations living in the higher malaria transmission districts and sub-districts, planning of malaria elimination from the study area might be feasible. Key words: Elimination, Harari region, Ethiopia, Incidence, Malaria, Sub-district, Stratification
Background: Ethiopia has shown a notable progress in reducing the burden of malaria over the last two decades. Based on the progress, the country shifted from control to elimination of malaria. This study was conducted to analyse trends in malaria cases and stratification of malaria incidence in the malaria elimination setting in eastern Ethiopia.Methods: A retrospective malaria data recorded from 2013 to 2019 were reviewed from Harari Region, eastern Ethiopia. In addition, three years malaria data were used to assess the sub-district (kebele) level stratification of malaria incidence.Results: A total of 44,882 (46.9%) malaria cases were detected from 95,629 malaria-suspected outpatient diagnosed in Harari Region from 2013 to 2019. Of these, 41,046 were confirmed malaria cases (microscopically and rapid diagnostic test) while 3,836 were reported as clinical cases. In the region, malaria trend was fluctuating year to year, the high peak was reported in 2016 but malaria cases showed decreasing trend in number of malaria cases from 2017 to 2019. Plasmodium falciparum, P. vivax and mixed infections were accounted for 69.2%, 30.6% and 0.2% of the cases, respectively. The malaria risk appears to be heterogeneous and varies between districts, higher number of malaria cases were recorded in Jenella, Erer and Amir Nur districts, and about 80% of the cases were from these districts. According to the latest (2019) sub-district (kebele) level epidemiological data of malaria stratification, 8.3% of the sub-districts in the Harari region reported no malaria and a majority (61.1%) of sub-districts reported fewer than five cases per thousand population. Furthermore, there were no high malaria strata in the Region. The highest peak of malaria cases in the Region was reported from September to November followed by from April to May.Conclusions: In the Harari Region, the retrospective malaria data showed a significant declining trend. Thus, if this achievement is sustained and scaling-up of the existing malaria prevention and control strategies by focusing on those populations living in the higher malaria transmission districts and sub-districts, planning of malaria elimination from the study area might be feasible.
BackgroundRapid antigen tests can help in the effective isolation of symptomatic cases and the systematic tracing of close contacts. However, their reliability must be validated before implementing them widely.MethodsA cross-sectional study was conducted on 236 COVID-19-suspected patients visiting four different health institutions in Harari Regional State, Harar, Eastern Ethiopia, from June to July 2021. Two nasopharyngeal samples were collected and processed by the Panbio™ Ag-RDT kit and qRT-PCR. The collected data were analyzed using SPSS version 25.0.ResultsThe Panbio tests had a sensitivity of 77.5% (95% CI: 61.6–89.2%) and a specificity of 98.5% (95% CI: 95.6–99.7%). It also had a positive predictive value of 91.2% (95% CI: 76.9–96.9%), a negative predictive value of 95.5% (95% CI: 92.3–97.4%), and a kappa of 0.81 (95% CI: 0.7–0.9). The test had a sensitivity of 94.4%, 100%, 100%, and 90% in the samples collected from patients within the 1–5 days post-onset of COVID-19 signs and symptoms, of age group ≤18 years old, with cycle threshold values of <20, and with household contact, respectively.ConclusionThis test can be used as point-of-care testing for the diagnosis of symptomatic patients with short clinical courses and contact with patients in households.
Rapid Antigen tests can help rapid detection, effective isolation of symptomatic cases, and systematic tracing of close contacts. However, the reliability of rapid antigen tests must be validated before they can be used widely. A cross-sectional study was conducted among 236 COVID-19 suspected patients visiting four health institutions in Harari Regional state, Harar, Eastern Ethiopia from June-July, 2021. Two Nasopharyngeal samples were also collected and processed by the Panbio™ Ag-RDT kit directly and RT-PCR. Data were analyzed using SPSS version 25.0. The Panbio tests has sensitivity of 77.5% (95% CI: 61.6% − 89.2%), specificity of 98.5% (95% CI: 95.6%- 99.7%), Positive Predictive Value of 91.2% (95% CI : 76.9% − 96.9%), negative Predictive Value of 95.5%(95%CI: 92.3%-,97.4%) and Kappa = 0.81, (95% CI: 0.7–0.9.).The test has sensitivity of 94.4% ,100%, 100% and 90% in sample collected from patients with in the 1–5 days duration of COVID post on set symptoms, age group < = 18 years old and cycle threshold (Ct) values of < 20 and source of contact from house hold respectively .The overall sensitivity of Panbio™ COVID-19 Ag Rapid Test Device is 77.5%. The test has sensitivity > = 90% in the sample collected from symptomatic patients in early clinical course, age of < = 18 years old, low Ct-values, and had contact with COVID patients in the household. Therefore, this test can be used as a point of care testing for diagnosis of symptomatic patients with shorted clinical course and contact with patients in the households.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.